Early Returns Podcast with Jan Baran - Josh Gerstein: SCOTUS, the Presidential Immunity Case Fallout, and the Dobbs Case Leak Investigation
Podcast: Post-Dobbs - One Year Later - Diagnosing Health Care
Early Returns Podcast with Jan Baran: The Honorable Thomas Griffith – Judiciously Ruling in the Face of Politics
Reproductive Rights in the Post-Dobbs Era
Podcast: Post-Dobbs - Considerations for Clinical Trials and Research - Diagnosing Health Care
Podcast: Post-Dobbs Access to Reproductive Health Care and Abortion-Inducing Drugs - Diagnosing Health Care
#WorkforceWednesday: EEOC Targets Abortion Travel, Midterm Results, and SCOTUS Declines COVID-19 WARN Act Case - Employment Law This Week®
In the Boardroom With Resnick and Fuller - Episode 2
Podcast: Post-Dobbs - Navigating the Fast-Changing and Uncertain Legal Landscape - Diagnosing Health Care
Let's Talk About the Constitutional Aspects of the Dobbs Decision
What Can The Handmaid’s Tale Teach Us About Corporate Abortion Policies? - Hiring to Firing Podcast
#WorkforceWednesday: Enforcement Risk Post-Roe, 11th State Passes Paid Family and Medical Leave, FTC/NLRB Join Forces - Employment Law This Week®
Dobbs on Demand: Navigating the Dobbs Decision: The Employment Law Perspective in the Workplace
Dobbs on Demand: Approaching Benefits in the New Legal Environment
Dobbs on Demand: Navigating the Line Between Healthcare and Crime in the Post-Dobbs Landscape
Employee Benefits Post-Dobbs: What Kinds of Assistance Can Employers Now Offer in Reproductive Healthcare?
State AG Pulse | Winner Takes All in Kansas
#WorkforceWednesday: Employers Respond to Dobbs, Implications of the Supreme Court's EPA Ruling, and Pay Increases for CA Health Care Workers - Employment Law This Week®
How the Dobbs Supreme Court Decision Affects Employee Benefits
Employment Law Now VI-118 - Overturning Roe v. Wade and the Impact on Employers and Employees
Since President Trump's inauguration, the Trump administration has issued a number of executive orders and policy actions with potential impacts for the life sciences industry. Notable actions include rescinding Biden-era...more
In recent months, several changes to healthcare rules regulations focusing on reproductive health care have been introduced. These include (1) privacy protections for reproductive health data under HIPAA, (2) expanding access...more
On April 22, 2024, the Office of Civil Rights issued a Final Rule titled HIPAA Privacy Rule to Support Reproductive Health Care Privacy (2024 Final Privacy Rule). Originally Published by the American Bar Association....more
Access to reproductive health care has been a part of the national debate for years, and even more so since 2022 when the US Supreme Court issued its ruling in Dobbs overturning decades of precedent established under Roe v....more
Mifepristone is safe for now. On June 13, 2024, the Supreme Court unanimously held that the plaintiffs — doctors and medical associations alike — lacked standing to challenge 2000 and 2019 FDA approvals of mifepristone (brand...more
On Friday, June 14, the Texas Supreme Court declined to consider a case that asked the Court to determine whether frozen embryos are persons or property under Texas law....more
New, or newly interpreted, state laws and court decisions governing abortion may directly affect access to medical care and treatment for patients who are, or who want to become, pregnant. They also have potential...more
On March 26, 2024, the Supreme Court heard arguments in the two consolidated cases concerning access to mifepristone pending before the Court, FDA v. Alliance for Hippocratic Medicine, Case No. 23-235 and Danco Laboratories,...more
On November 7, 2023, the citizens of the state of Ohio voted to codify reproductive rights, including the right to abortion, in the state constitution. In 2019, Ohio banned nearly all abortions once fetal cardiac...more
On April 7, 2023, two federal judges in Texas and Washington State issued dueling opinions about the abortion medication Mifepristone, just hours apart. These two decisions come in the midst of growing tension about abortion...more
On January 3, 2023, FDA released an updated Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. The updated REMS follows a December 2021 FDA announcement that it would eliminate the requirement that mifepristone...more
On January 3, 2023, the U.S. Food and Drug Administration (FDA) modified its risk evaluation and mitigation strategy (REMS) program (“Mifepristone REMS Program”) to provide a process for pharmacies to become certified to...more
A podcast series in collaboration with PLUS, the Professional Liability Underwriting Society. Episode Two Resnick and Fuller focus on the potential legal liabilities in the wake of the U.S. Supreme Court’s decision in Dobbs...more
Congress faces a crowded agenda this fall comprised of must-pass policy initiatives and potential political messaging opportunities in the lead up to the November midterm elections. With control of both chambers at stake, the...more
The Paris office of Hogan Lovells is pleased to provide this English language edition of our monthly e-newsletter, which offers a legal and regulatory update covering France and Europe for March 2017. ...more